Biolinq

Biolinq is pioneering a new category of 'Biowearables' with its needle-free, intradermal biosensor platform. The company's first FDA-cleared product, the Biolinq Shine™, is a qualitative glucose sensor for non-insulin-using adults, featuring a unique color-coded LED system for real-time feedback. With over $120 million invested and a leadership team with deep experience from companies like Dexcom and Medtronic, Biolinq aims to expand its platform beyond glucose to other biomarkers, targeting the massive metabolic health and digital wellness markets. Its core innovation lies in a comfortable, microarray sensor architecture designed for scale and multi-analyte functionality.

Proprietary microarray platform of ultra-small intradermal electrochemical biosensors, integrated with accelerometer and ambient light sensor, designed for needle-free, continuous multi-analyte sensing.

Biolinq faces intense competition in glucose sensing from dominant players like Dexcom, Abbott (FreeStyle Libre), and Medtronic, who have vast resources and market share. Its needle-free differentiation targets a specific user experience gap. It also competes in the broader digital wellness space with fitness trackers and other biowearables, though its medical-grade sensor platform is a key distinction.